NSE · COHANCE · Pharmaceuticals
Cohance Lifesciences Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹360 Cr with net profit ₹1 Cr — a 0.39% net margin, versus 7.78% the period before.
Shareholding
As of 2026-06-30
- Promoter57.49%
- Public15.93%
- FII6.5%
- DII20.09%
99,149 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 3.85× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #21 of 102 by market cap · medians across 49 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,43,877 Cr | 35.13 | 5.31 | 13.74% | 20.29% |
| Zydus Lifesciences Ltd. | ₹1,10,922 Cr | 22.72 | 4.09 | 18.59% | 16.09% |
| Cipla Ltd. | ₹1,10,677 Cr | 30.93 | 3.21 | 11.27% | 12.06% |
| Laurus Labs Limited | ₹1,05,037 Cr | 96.05 | 19.82 | 16.77% | 15.04% |
| Aurobindo Pharma Ltd. | ₹96,088 Cr | 25.41 | 2.54 | 9.25% | 10.7% |
| Dr Reddys Laboratories Ltd. | ₹95,237 Cr | 29.56 | 2.5 | 11.07% | 9.73% |
| Lupin Limited | ₹94,837 Cr | 15.92 | 4.22 | 23.76% | 18.72% |
| Mankind Pharma Limited | ₹92,770 Cr | 43.48 | 5.69 | 11.74% | 13.86% |
| Glenmark Pharmaceuticals Ltd. | ₹67,988 Cr | 21.78 | 6.47 | 28.08% | 10.22% |
| Biocon Ltd. | ₹63,835 Cr | 87.43 | 1.85 | 1.14% | 2.89% |
| Cohance Lifesciences Ltd.(this company) | ₹17,026 Cr | 158.36 | 4.35 | 5.05% | 4.96% |
AI analysis
AI-generated · google/gemini-2.5-flashCohance Lifesciences Ltd. is listed with a market capitalization of Rs 16906 Cr. The company reported revenue of Rs 1256.14 Cr for the latest financial year. The company's PE ratio is 108.7, and its book value is Rs 90.95. Earnings per share stand at Rs 10.67, with a Return on Equity (ROE) of 12.5% and Return on Capital Employed (ROCE) of 5.467%.
Positives
- +The company maintains a low debt-to-equity ratio of 0.04.
- +Promoter shareholding is at 57.488% as of Jun 2026.
Negatives
- −Promoter holding has decreased from 60.0004% in Mar 2021 to 57.488% in Jun 2026.
- −94.56% of promoter shares are pledged.
- −The company's net profit declined from Rs 153.07 Cr in Dec 2024 to Rs 19.55 Cr in Mar 2026.
- −The company is under LT-ASM surveillance, specifically 'ASM 1'.
- −Return on Capital Employed (ROCE) is 5.467%, which is lower than Return on Equity (ROE) of 12.5%.
Financial Performance
The company's latest annual revenue was Rs 1256.14 Cr. Quarterly reports show a decline in revenue, from Rs 676.23 Cr in Dec 2024 to Rs 619.12 Cr in Mar 2026. Net profit also decreased over the same period, from Rs 153.07 Cr in Dec 2024 to Rs 19.55 Cr in Mar 2026.
Profitability & Returns
Cohance Lifesciences Ltd. has a Return on Equity (ROE) of 12.5% and a Return on Capital Employed (ROCE) of 5.467%. Earnings per share (EPS) for the company are Rs 10.67. The company does not report a profit margin in the provided data.
Balance Sheet
The company maintains a low debt-to-equity ratio of 0.04. The book value per share is Rs 90.95. No further details on assets or liabilities are provided in the available data.
Ownership & Pledges
Promoter holding stands at 57.488% as of Jun 2026, while public shareholding is 15.9269%. Notably, 94.56% of promoter shares are pledged. The total number of shareholders is 99149.
Regulatory & Surveillance
Cohance Lifesciences Ltd. is under LT-ASM surveillance, specifically 'ASM 1', indicating heightened monitoring by regulatory authorities.
Data as of — price: 2026-09-10 · financials: Jun 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.